Skip to main content

Table 2 Age and sex distribution for the different treatment groups (“concomitant LABA and ICS users”, “switchers”, “non-concomitant LABA and ICS users”, “LABA users without ICS”, “ICS users without LABA”) for the year 2008

From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial

  Concomitant LABA and ICS users Switchers Non-concomitant LABA and ICS users LABA users without ICS ICS users without LABA
N (%) 177,159 (57.6%) 14,899 (4.8%) 1,936 (0.6%) 16,749 (5.4%) 96,615 (31.4%)
Age in years (mean ± SD) 49.1 ± 21.9 59.1 ± 17.8 55.4 ± 20.2 58.0 ± 19.3 37.5 ± 24.9
Females (n [%]) 98,071 (55.4%) 8,258 (55.4%) 1,184 (61.2%) 8,705 (52.0%) 52,907 (54.8%)